Issue two of the ESC Bench to Bedside series highlights the emerging role of GLP-1 receptor agonists (GLP-1 RAs) and GIP agonists in the management of heart failure with preserved ejection fraction (HFpEF). This edition guides participants through a structured journey, starting with the mechanisms of action of these therapies and their potential benefits for patients. It then explores key findings from major clinical trials, including SELECT, STEP-HFpEF, and SUMMIT, to help clinicians identify which patients are most likely to benefit. The series concludes by translating this evidence into practical guidance on patient selection, dosing, safety monitoring, and addressing remaining knowledge gaps.

By combining mechanistic insights, trial evidence, and practical application, Issue two equips cardiology professionals with the insights needed to integrate GLP-1 RAs and GIP agonists into patient care safely and effectively.